Journal of Clinical Oncology
Articles in this Issue
Characterisation of ductal carcinoma in situ (DCIS) using mass spectrometry imaging towards near realtime margin assessment.
3140 Background: Imprecision in breast-conserving surgery leads to high national average high rates of reoperative intervention. In line with updated marg...
Social vulnerability by neighborhood of association correlates with CAR T referrals.
7025 Background: Chimeric antigen receptor T (CAR T) cell therapies are effective for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and...
Pharmacoeconomic analysis of perioperative chemo-immunotherapy in resectable stage III non small cell lung cancer (NSCLC): Survival time cost-efficacy based on NADIM 2 trial.
e23141 Background: Neoadjuvant and perioperative chemoimmunotherapy is increasingly used in resectable NSCLC. Several trials achieved improvement in EFS a...
Impact of somatic/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume.
5094 Background: The impact of HRR mutations in castration-resistant prostate cancer has previously been reported, but their role in mHSPC patients (pts)...
Fragmentation landscape of cell-free DNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by race.
e17028 Background: Prostate cancer (PCA) is the most diagnosed cancer, more than 1.2 million new cases are diagnosed. PCA-related deaths exceed 350,000 an...
Comparative analysis of survival outcomes in infused versus not-infused patients with aggressive B-cell lymphoma referred for CART.
7056 Background: Chimeric antigen receptor T-cell therapy (CART) has changed the treatment paradigm for patients (pts) with relapsed/refractory (R/R) aggr...
Outcomes of initial vs delayed docetaxel therapy in veterans with metastatic hormone sensitive prostate cancer and high volume of disease.
5097 Background: Docetaxel (DOC) continues to demonstrate efficacy in metastatic hormone sensitive prostate cancer (mHSPC), particularly in combination wi...
Incidence and impact of incidental pulmonary embolism in solid cancer patients.
e23272 Background: Incidental pulmonary embolism (IPE) refers to asymptomatic pulmonary embolism (PE) detected during routine imaging in cancer patients....
National trends in mortality of pancreatic cancer in adults aged 70 and older across 204 nations: A global burden of disease analysis (1990–2021).
e16420 Background: Pancreatic cancer (PC) typically follows an indolent course and is often diagnosed at an advanced stage, contributing to its high morta...
Radiotherapy utilization at the fourth most populous province in Indonesia: A single centre study.
1606 Background: Cancer continues to grow as a health burden in Indonesia, with the current cumulative cancer risk at 14.0%. Along with the rising rate of...
Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
549 Background: Breast cancer (BC) treatment selection is traditionally guided by clinical characteristics. However, as clinical characteristics cannot ca...
Impact of metastatic sites on response to immunotherapy in patients with advanced or recurrent endometrial cancer.
e17632 Background: Patients with advanced or recurrent endometrial cancer have a median progression-free survival (PFS) of 3-6 months and a 5-year surviva...
Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone (CMOP) for patients with treatment-naïve peripheral T-cell lymphomas (PTCLs): Extended follow-up analysis of a multicenter, open-label, single-arm, phase Ib study.
7048 Background: PTCLs represent a heterogeneous group of lymphomas generally majority of patients (pts) associated with a poor prognosis when treated wit...
Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in <i>ESR1</i> and <i>AKT</i> pathway: A retrospective analysis.
e13084 Background: HR+/HER2- MBC remains an incurable disease. In published series, the co-occurrence rate of ESR1 and...
Assessing the effects of financial toxicity on quality of life among hematopoietic stem cell transplantation recipients.
1593 Background: “Financial toxicity” refers to the financial burden imposed by treatment costs on individuals with cancer, constituting a major barrier t...
Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).
7008 Background: There is an unmet need for new treatment approaches for patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL)...
Analysis of deep learning for automated recognition of immune cells interacting with CTCs for prognostic assessment in cancer.
e13028 Background: Liquid biopsy has emerged as a powerful, minimally invasive tool for predicting treatment response and survival in breast and other adv...
Relapse patterns, risk factors, re-resectability and survival after curative treatment for metastatic colorectal cancer (mCRC): A RAXO substudy.
3566 Background: In mCRC, metastasectomy and/or local ablative treatment (LAT) cures some. However, over 70% of the patients relapse, with liver, lung and...
Fear of cancer recurrence in long-term colorectal cancer survivors: A randomized controlled trial of a therapist-guided eHealth intervention.
12004 Background: Despite the availability of effective interventions, fear of cancer recurrence (FCR) remains a prevalent and significant concern among c...
Assessment of smartwatch-based electrocardiogram (ECG) abnormality detection among childhood cancer survivors.
10069 Background: Childhood cancer survivors (CCS), exposed to cardiotoxic cancer therapies, are at lifelong risk for premature cardiovascular disease. Ho...
A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION).
5589 Background: Pamiparib is a selective PARP1/2 inhibitor, while surufatinib targets VEGFR1-3, FGFR1, and CSF-1R. We evaluated the efficacy and safety o...
Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.
TPS1130 Background: Resistance to CDK4/6 inhibitors (CDK4/6i) is common for many patients with HR+/HER2- advanced or metastatic breast cancer, therefore n...
Prevalence of homologous recombination deficiency in Korean patients with epithelial ovarian cancer.
e17584 Background: The prevalence of homologous recombination deficiency (HRD) in high-grade serous carcinoma (HGSC) of epithelial ovarian cancer (EOC) is...
Genomic and immunophenotypic landscape of early-stage pulmonary carcinoid tumors.
8030 Background: Pulmonary carcinoids (PCs), which encompass atypical carcinoids (ACs) and typical carcinoids (TCs), represent a rare category of lung can...
Targeting histone demethylation to knock down <i>HOXA-AS2</i> and <i>HOXA-AS3</i> , outcome-determining lncRNAs in multiple malignancies: Effect of deferiprone, a mechanism-based disruptor of KDM6B catalysis.
e15153 Background: HOXAantisense RNAs 2 and 3 ( HOXA-AS2 , -AS3 ) are lncRNAs that determine outcome in ma...